Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.
Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, Oosting SF, Jalving M, Timens W, Brouwers AH, Kwee TC, Gietema JA, Fehrmann RSN, Fine BM, Sanabria Bohórquez SM, Yadav M, Koeppen H, Jing J, Guelman S, Lin MT, Mamounas MJ, Eastham JR, Kimes PK, Williams SP, Ungewickell A, de Groot DJA, de Vries EGE. Kist de Ruijter L, et al. Among authors: giesen d. Nat Med. 2022 Dec;28(12):2601-2610. doi: 10.1038/s41591-022-02084-8. Epub 2022 Dec 5. Nat Med. 2022. PMID: 36471036 Free PMC article. Clinical Trial.
89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.
Pool M, Terwisscha van Scheltinga AGT, Kol A, Giesen D, de Vries EGE, Lub-de Hooge MN. Pool M, et al. Among authors: giesen d. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1328-1336. doi: 10.1007/s00259-017-3672-x. Epub 2017 Mar 19. Eur J Nucl Med Mol Imaging. 2017. PMID: 28315949 Free PMC article.
Theranostics Using Antibodies and Antibody-Related Therapeutics.
Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, Lub-de Hooge MN, Brouwers AH, de Vries EGE. Moek KL, et al. Among authors: giesen d. J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S. doi: 10.2967/jnumed.116.186940. J Nucl Med. 2017. PMID: 28864618 Free article. Review.
First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody.
Kist de Ruijter L, Hooiveld-Noeken JS, Giesen D, Lub-de Hooge MN, Kok IC, Brouwers AH, Elias SG, Nguyen MTL, Lu H, Gietema JA, Jalving M, de Groot DJA, Vasiljeva O, de Vries EGE. Kist de Ruijter L, et al. Among authors: giesen d. Clin Cancer Res. 2021 Oct 1;27(19):5325-5333. doi: 10.1158/1078-0432.CCR-21-0453. Clin Cancer Res. 2021. PMID: 34253583
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, Brouwers AH, Hiltermann TJN, van der Wekken AJ, Hijmering-Kappelle LBM, Timens W, Elias SG, Hospers GAP, Groen HJM, Uyterlinde W, van der Hiel B, Haanen JB, de Groot DJA, Jalving M, de Vries EGE. Kok IC, et al. Among authors: giesen d. Ann Oncol. 2022 Jan;33(1):80-88. doi: 10.1016/j.annonc.2021.10.213. Epub 2021 Nov 1. Ann Oncol. 2022. PMID: 34736925 Free article.
89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.
Broer LN, Knapen DG, Suurs FV, Moen I, Giesen D, Waaijer SJH, Indrevoll B, Ellingsen C, Kristian A, Cuthbertson AS, de Groot DA, Cole PE, de Vries EGE, Hagemann UB, Lub-de Hooge MN. Broer LN, et al. Among authors: giesen d. J Nucl Med. 2022 Nov;63(11):1715-1721. doi: 10.2967/jnumed.121.263079. Epub 2022 Apr 14. J Nucl Med. 2022. PMID: 35422447 Free article.
58 results